Pfizer is a leading research-based biopharmaceutical company, and has made an equity investment in Cellectis. Together, we are collaborating globally on 15 targets, including the first allogeneic BCMA CAR-T, which can have powerful activity against cancers like measurable multiple myeloma.
“Cellectis and Pfizer share the same commitment to develop unique allogeneic cancer therapies that will benefit patients around the world. Combining Cellectis’ innovative allogeneic cell approach and scientific gene modification expertise with Pfizer’s deep oncology and immunology experience in translating discovery into patient impact, creates a world-class partnership designed to advance a new generation of CAR-T immunotherapies for cancer patients with urgent medical needs.”
Mikael Dolsten, MD, PhD, President of Worldwide Research & Development at Pfizer